Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5308499 | 1.00 | TAAR1 (0.51) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL19738039 | 0.85 | KMT2A (0.50) | MEN1KMT2ATDP1 | |
| SCHEMBL6795931 | 0.84 | MEN1 (0.55) | TAAR1MEN1KMT2A | |
| SCHEMBL3058722 | 0.84 | SIGMAR1 (0.57) | SIGMAR1KMT2A | |
| SCHEMBL19738025 | 0.80 | GAA (0.47) | MEN1KMT2ATDP1 | |
| SCHEMBL5234365 | 0.80 | HTR1A (0.49) | MAOAMEN1KMT2ATDP1 | |
| SCHEMBL5308249 | 0.80 | HTR2A (0.60) | TAAR1 | |
| SCHEMBL5308245 | 0.80 | HTR2A (0.60) | TAAR1 | |
| SCHEMBL21300617 | 0.79 | BCHE (0.67) | TDP1 | |
| SCHEMBL20553334 | 0.79 | PTGS2 (0.55) | TAAR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | TAAR1 1075/4885SLC6A2 97/4885MAOA 21/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | TAAR1 1075/4885SLC6A2 97/4885MAOA 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.